natgillin/translations-raw huggingface dataset:
An activator composition mixable with a non-OPC hydraulically-active material comprising ground granulated blast furnace slag (GGBS), pulverised fuel ash (PFA) or a mixture of GGBS and PFA, the activator composition comprising an activator, which is CaO or lime, and a polycarboxylate-ether-based (PCE) superplasticiser. 
Cementno vezivo koje sadrži barem 90 masenih % ne-OPC hidraulički aktivnog materijala koji sadrži mljevenu granuliranu zguru iz visokih peći (GGBS), leteći pepeo (PFA) ili smjesu GGBS i PFA, više od 0.1% i manje od 9.5 masenih % aktivatora, koji je CaO ili vapno, i superplastifikator.
* Atomic occupancy factor is 0.5 due to disorder of 2-butyne-1,4-diol solvent in the crystal structure. 
Kristalna struktura spoja s formulom I naznačena time da je u obliku njegovog propilen glikol solvata.
A compound according to claim 71 of formula (IIID) 
Spoj u skladu s patentnim zahtjevom 71, naznačen time što je spoj formule (TII?)
The inhibitor of Notch signaling pathway of any one of the preceding claims, wherein the Notch dependent cancer is selected from the group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, and colorectal cancer. 
Spoj za upotrebu prema zahtjevu 1 naznačeno time da je Notch ovisni rak izabran među grupom koja se sastoji od akutne limfoblastične leukemije T stanica (T-ALL), kronične mijeloične leukemije (CML), kronične limfocitne leukemije (CLL), limfoma stanica rubne zone (MCL), raka dojke, raka gušterače, raka prostate, melanoma, moždanih tumora, tumorske angiogeneze, i raka debelog crijeva.
it has an increased sialylation degree with an amount of NeuNAc on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition which is at least 15% higher compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
- ima povećani stupanj sijaliliranja količinom NeuNAc na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod molekula proteina u navedenom pripravku s molekulom proteina koja je najmanje 15% veća u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
redirecting the heat and/or water for further use. 
- < preusmjeravanje topline i/ili vode za daljnju uporabu.
R' and R" together form an acetal protecting group; 
R'1 R" zajedno tvore acetalnu zaštitnu skupinu;
Alternatively, the oral preparations can be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. 
Alternativno, oralni pripravci mogu biti u obliku praha koji se može rekonstruirati vodom ili nekim drugim prikladnim tekućim punilom prije uporabe.
is a hydroxyl protecting group. 
P, je hidroksil zaštitna skupina.
The isolated molecule of claim 1, wherein the therapeutic agent is a toxin, an siRNA, a chemotherapeutic agent or a therapeutic antibody. 
Izolirano monoklonsko protutijelo za upotrebu za liječenje raka prema zahtjevu 5, naznačeno time da terapeutsko sredstvo toksin, siRNA, kemoterapijsko sredstvo ili terapijsko protutijelo.
A pharmaceutical composition for use in treating and/or preventing cardiovascular-related diseases in a subject, wherein the subject is on concomitant statin therapy and has a fasting baseline triglyceride level of about 200 mg/dL to about 500 mg/dL, wherein the cardiovascular-related disease is myocardial infarction and/or stroke, and wherein the pharmaceutical composition comprises EPA. 
Farmaceutski pripravak namijenjen upotrebi za snižavanje triglicerida i LDL-C kod subjekta koji je na stabilnoj terapiji statinom i koji ima osnovne trigliceride natašte od oko 200 mg/dL do oko 500 mg/dL, pri čemu pripravak sadrži najmanje oko 96 masenih %, svih prisutnih masnih kiselina, etil estera eikozapentaenske kiseline (etil-EPA), pri čemu se oko 4 g pripravka dnevno daje subjektu u periodu od 12 tjedana, te pri čemu subjekt ima smanjenje natašte triglicerida i LDL-C u usporedbi s kontrolnim subjektom održavanim na stabilnoj terapiji statinom bez istovremene primjene pripravka.
In a still further preferred embodiment of the pharmaceutical composition according to the invention, the adjuvant is imiquimod or resimiquimod. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, koji dodatno sadrži najmanje jednu stanicu koja predstavlja antigen.
sucrose. A lyophilized pharmaceutical preparation according to claim 1, wherein the amount of sucrose is 10-100 % by weight of said melphalan flufenamide hydrochloride (J1). 
Liofilizirani farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je količina saharoze od 10 do 100 % težinskog udjela navedenog melfalan flufenamid hidroklorida (T1).
The magnesia cement of any one of claims 1 to 9, characterized in that the slightly soluble carboxylic acids are selected from the group consisting of fumaric acid, adipic acid, benzoic acid, phtalic acid, phtalic anhydride, and sorbic acid, and wherein those acids that are solid at room temperature have an average particle size of less than 60 µm, typically of from 1 to 55 µm. 
Magnezijski cement prema bilo kojem od zahtjeva 1 do 9, naznačen time što malo topljive karboksilne kiseline su odabrane od skupine koja se sastoji od fumarne kiseline, adipinske kiseline, benzojeve kiseline, ftalne kiseline, ftalnog anhidrida i sorbinske kiseline, i pri čemu one kiseline koje su krute na sobnoj temperaturi imaju prosječnu veličinu čestice manju od 60 µm, tipično od 1 do 55 µm.
Preform according to one of the claims 1 to 7, characterized in that said preform has a base (30), wherein said intermediate layer (2) has a bend (29) toward said bottom and which extends further to the free end (31) thereof. 
Preoblikovani element prema jednom od Zahtjeva 1 do 7, naznačen time, što navedeni preoblikovani element posjeduje temelj (30) gdje navedeni među-sloj (2) posjeduje zakrivljenje (29) prema navedenom dnu i što se pruža dalje do njegovog slobodnog kraja (31).
tuberculosis, bladder cancer, 
(11) karcinoma mjehura,
Method according to one of the preceding claims, characterised in that a selectable dataset is transferable as a datastream from the database (4) via the server (3) and the communication channel (2') to a mobile equipment (5). 
Postupak temeljem jednog od prethodnih zahtjeva, naznačen time da se skup podataka, koji se može izabrati, može prenijeti kao tok podataka iz baze podataka (4) putem servera (3) i komunikacijskog kanala (2') na mobilni uređaj
The use of any one of claims 1 to 7, wherein the AAV vector is a single stranded AAV vector. 
AAV vektor iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu je AAV vektor AAV2/9 vektor koji sadrži AAV2- derivirani genom u AAV9-deriviranoj kapsidi.
A distributed computing system (1) for synchronizing data-sets stored on different communication devices which are connected via communication links, comprising a first communication device (10) which comprises the following features: 
Distribuirani računalni sustav (1) za sinkroniziranje podatkovnih nizova pohranjenih u različitim komunikacijskim uređajima međusobno povezanim komunikacijskim vezama, naznačen time što sadrži a) prvi komunikacijski uređaj (10), koji sadrži sljedeće elemente:
Composition according to claim 3, comprising cytisine having particle size d90 below 80 µm. 
Sastav prema zahtjevu 2, obuhvaćajući citizin koji ima veličinu čestice d90 ispod 80 µm.
The invention relates to a device comprising a stable dry powder of thyroid hormone, said device: 
Izum se odnosi na uređaj koji sadrži stabilni suhi prah s tiroidnim hormonom, navedeni uređaj:
triple-negative breast cancer (TNBC); 
(iti) trostruko negativni rak dojke (TNBC);
or a pharmaceutically acceptable salt thereof, with a compound of formula (9): 
(8) ili njegove farmaceutski prihvatljive soli, spojem formule (9):
The tablet for oral administration according to claim 1, wherein the tablet contains 180 mg of deferasirox or a pharmaceutically acceptable salt thereof. 
3. < Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da tableta obuhvaća 180 mg deferasiroksa ili njegove farmaceutski prihvatljive soli.
US20090030002; U.S. published application no. 
US (73) Nositelj patenta:
The inventor has identified infectious agents that can grow in the conditions used for growing influenza viruses in cell culture but that do not grow in hen eggs. These infectious agents represent a new contamination risk for influenza vaccines that was never of concern for traditional influenza vaccines. Thus the invention provides a process for preparing an influenza vaccine from influenza virus that has been grown in a culture of a Vero cell line, comprising a step in which the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said Vero cell line but that does not grow in embryonated hen eggs, as defined in the claims. 
Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxgackievirusi od Fnterovirusa iz familije Picornaviridae, Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca.
Use of the system according to claim 8 for establishing a density of zooplankton copepods in an aqueous solution. 
Uporaba sustava prema jednom od zahtjeva 5-8 naznačena time da je za određivanje gustoće zooplankton kopepoda (11) u vodenog otopini.
The combination according to claim 1 wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
Kombinacija u skladu s patentnim zahtjevom 1 ili 2, naznačena time što je farmaceutski prihvatljiva sol spoja formule (I) natrijeva sol.
The aqueous solution is acidified to pH ~2 by dropwise addition of dil. 
Vodenu otopinu zakiseli se do pH 2 ukapavanjem razrijeđene HCI.
Attempts to modulate hepatic glucose production (HGP) with gluconeogenesis inhibitors have yielded limited success. 
Napori usmjereni na moduluaciju proizvodnje glukoze u jetri (HGP) putem inhibitora glukoneogeneze imali su ograničeni uspjeh.
generation of pulsed DC discharge plasma from atmospheric air in order to complement the sterilization and elimination of residues; and 
- > generiranje plazme pulsnim pražnjenjem istosmjerne struje iz atmosferskog zraka kako bi se dodatno pojačala sterilizacija i uklonili ostaci;
Generally the compounds exhibit favourable physical properties such as a high solubility whilst retaining high antiproliferative activity. 
Općenito spojevi pokazuju poželjna fizikalna svojstva, poput dobre topljivosti, dok istovremeno zadržavaju visoku antiproliferativnu aktivnost.
The product of any preceding claim, wherein the nucleic acid molecules of the biological sample have been amplified using a polymerase chain reaction. 
Postupak prema zahtjevu 1, naznačen time, da su molekule nukleinske kiseline iz biološkog uzorka pojačane uporabom lančane reakcije polimeraze.
A subsequent polymerase chain reaction (PCR) was performed using the cDNA as template and the oligonucleotides TTTACGCGTGGCCATGCCCATCATGGGCTCCTC and TTTCTAGAATCAGCACACTCCTGCTCCATC as primers for the amplification. 
Posljedično, događa se lančana reakcija polimeraze (PCR) korištenjem cDNA kao predloška i oligonukleotida TTTACGCGTGGCCATGCCCATCATGGGCTCCTC i TTTCTAGAATCAGGACACTCCTGCTCCACT kao primera za amplifikaciju.
providing a container comprising a base and a continuous side wall upstanding from the base with a peripheral flange formed along the upper, in use, edge of the continuous side wall, thereby forming a tray, wherein said base and side wall consist essentially of polyethylene terephthalate (PET), and at least one denesting recess located in a denesting area, wherein the denesting area is relieved relative to the upper surface of the flange and extends partially or completely along the inner periphery of the flange, and 
pružanje posude koja sadrži osnovu i kontinuirani bočni zid koji se proteže čvrsto okomito na osnovu sa obodom formiranim duž gornjeg, pri upotrebi, ivice kontinuiranog bočnog zida, pri čemu se osnova i kontinuirani bočni zid u osnovi sastoje od polietilen tereftalata (PET); i
is is alkyl, aminoalkyl, or alkanol; each X13 is independently hydrogen, hydroxy, alicyclic, amino, aminoalkyl, halogen, alkyl, heteroaryl, boronic acid or aryl; 
X, je alkil, aminoalkil ili alkanol; svaki X;3s je nezavisno vodik, hidroksi, alicikličan, amino, aminoalkil, halogen, alkil, heteroaril, boronska kiselina ili aril; z je broj koji nije negativan; 1 amin koji odgovara Formuli 2b sadrži najmanje jednu alilnu skupinu.
A safety mechanism (401) as claimed in anyone of claims 1 to 4, wherein the receiver (360) is an electromagnetic receiver and the signal is an electromagnetic signal. 
Bunar (10) sukladno patentnom zahtjevu 1 i 2, naznačen time, da je prijemnik (360) ili primopredajnik elektromagnetski prijemnik ili primopredajnik (250, 360) respektivno i signal je elektromagnetski signal.
Thus, for any protein it is a challenge to establish a purification process allowing for sufficient purity while retaining the biological activity of the protein. 
Tako, za bilo koji protein izazov je uspostaviti proces pročišćavanja koji omogućava dovoljnu čistoću te koji ne narušava biološku aktivnost proteina.
The lentiviral vector of claim 1, wherein the polynucleotide encodes a CAR as set forth in any one of SEQ ID NOs: 2-3. 
Lentivirusni vektor iz stavka 1, pri čemu polinukleotid kodira CAR kako je navedeno u bilo kojem od SEQ ID NOs: 2-3.
obtaining the PLP corresponding to the identifier of the PLP and the identifier of the transmission system included in the NIT; and 
H1807 Dobivanje PLP-a u okviru signala koji odgovara identifikatoru PLP-a i identifikatoru C2 sustava
The thermoplastic film according to any preceding numbered embodiment, wherein the there are at least three fibre elements extruded on the base film, preferably at least eight fibre elements. 
Termoplastična folija sukladno bilo kojem od prethodnih zahtjeva, pri čemu su barem tri vlaknasta elementa izbočena, poželjno barem osam vlaknastih elemenata.
The process of claim 7, wherein said lithium is in the form of lithium wires. 
Postupak sukladno zahtjevu 7, naznačen time, što je navedeni litij u obliku litijskih žica.
Ar is selected from the group consisting of phenyl, substituted phenyl, thiophen-yl, substituted thiophen-yl, pyridinyl, substituted pyridinyl, thiazolyl, and substituted thiazolyl. 
AT je odabran iz skupine koju čine: fenil, supstituirani fenil, tiofen-il, supstituirani tiofen-il, piridinil, supstituirani Piridinil, tiazolil i supstituirani tiazolil.
Subsequently, the so obtained raw veneer mostly having thicknesses of from about 0.45 mm to 2.5 mm, preferably of from 0.45 mm to 0.8 mm, is dried within some minutes, preferably at temperatures above 100 °C. 
Nakon toga se tako dobiveni sirovi furnir, koji najčešće ima debljinu od oko 0.45 mm do 2.5 mm, poželjno od 0.45 mm do 0.8 mm, suši kroz nekoliko minuta, poželjno na temperaturi iznad 100%C.
Measurement of fluorescence due to GnRH stimulated (50 ul of 20 nM, or 4 nM final) Ca++ flux is performed according to manufacturer's instructions on a FLIPR system (Molecular Devices, FLIPR384 system, Sunnyvale, Calif.) following a 1-minute incubation with 50 ul of antagonist at varying concentrations. 
Mjerenje fluorescencije zbog GnRH-om stimuliranog (50 ul 20 nM, ili 4 nM, konačno) protoka Ca" proveden je prema uputama proizvođača, na sustavu FLIPR (Molecular Devices, FLIPR384 system, Sunnyvale, CA) nakon 1-minutnog inkubiranja s 50 pl antagonista u različitim koncentracijama.
A composition comprising (i) at least one compound of claim 1, or its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures thereof, or at least one pharmaceutically acceptable salt thereof and (ii) at least one pharmaceutically acceptable carrier. 
Sastav, naznačen time, da obuhvaća (i) najmanje jedan spoj prema zahtjevu 1, ili njegovu racemičnu smjesu, njegov enantiomer, dijastereomer, tautomer, ili njihove mješavine, ili najmanje jednu njegovu farmaceutski prihvatljivu sol te (11) najmanje jedan farmaceutski prihvatljiv nosač.
The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-7, wherein the heavy chain has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10-33, 38-80, 160-183, 222-244, and 245. 
Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 6, naznačen(o) time, da jaki lanac ima jednu amino kiselinsku sekvencu od SEQ ID NO:46 ili od SEQ ID NO: 51.
The compounds of the present invention can also be administered in a targeted drug delivery system, such as in a liposome coated with endothelial cell-specific antibody. 
Spojeve prema ovom izumu također se može primijeniti u sustavima za ciljani unos lijeka, primjerice u liposomima obloženim protutijelom specifičnim za endotelne stanice.
any combination thereof. 
(1) bilo koje njihove kombinacije.
A compound of formula (I), or a salt thereof, for use in the treatment or prevention of pain, inflammation or a neurodegenerative disease as defined in claim 12, wherein: 
Spoj formule (I), ili njegova sol, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju boli, upale ili neurodegenerativne bolesti u skladu s patentnim zahtjevom 12, gdje:
Apparatus according to claim 5, wherein guide means is provided in the form of guide rollers adapted to run along a guide track in order to assist controlled relative movement of the first and second mounting members due to the excessive G-force. 
Uređaj prema zahtjevu 5, gdje postoje vodilice u obliku valjaka prilagođenih da idu po traci radi pomaganja kontroliranom relativnom pomaku prvog i drugog ugradbenog člana zbog prekomjerne G-sile.
The method of claim 2, wherein if the biological sample is positive for JCV antibody then the subject is not a candidate to receive treatment with an immunomodulator. 
(ii) nije kandidat da primi liječenje imunomodulatorom ako je biološki uzorak pozitivan na protutijelo protiv JCV; ili
and wherein each peptide comprises no more than 30 amino acids. A pharmaceutical composition comprising the peptide mixture according to claim 1 and a pharmaceutically acceptable carrier, diluent and/or excipient. 
Farmaceutska kompozicija koja sadrži peptidnu smjesu iz bilo kojeg od patentnih zahtjeva 1-3, ili smjesu T stanica iz patentnog zahtjeva 4 i farmaceutski prihvatljiv nosač, razblaživač i/ili ekscipijens.
The dispensing apparatus has a complicated design, comprising a vast number of parts, the parts themselves being elaborate, costly devices. 
Aparat za točenje ima kompliciranu konstrukciju, koja uključuje velik broj dijelova, pri čemu su sami dijelovi fine izrade i skupe naprave.
Under these conditions a resolvation and reprecipitation takes place. 
Pod tim uvjetima odvija se ponovno otapanje i ponovna kristalizacija.
The inlet valve connects the canister liquid reservoir with the liquid to a metering chamber while the outlet valve connects the metering chamber to the atmosphere. 
Ulazni ventil povezuje spremnik zalihe s tekućinom prema odmjernoj komori, dok izlazmi ventil povezuje odmjernu komoru prema atmosferi.
only two of R7-R12 is different from hydrogen and the substituents are selected independently from the group consisting of hydrogen, methyl, fluoro, chloro or methoxy. 
Samo dva R'-R'" su različita od vodika a supstituenti su izabrani, nezavisno, iz grupe koja se sastoji od vodika, metila, fluora, klora ili metoksi
use in the treatment of cancer wherein the cancer is bladder cancer with a FGFR3 point mutation; or 
(xi) uporaba u liječenju karcinoma, gdje je karcinom karcinom mokraćnog mjehura s točkastom mutacijom FGFR3; ili
The process according to claim 1, wherein the chloromethyl oxazolidinone compound of formula VII is converted in step (b) to the acetyl derivative of the compound of formula VI as defined in claim 1, which comprises reacting the said chloromethyl oxazolidinone with anhydrous sodium acetate in a reaction solvent to give the acetyl compound of formula VI 
Postupak prema zahtjevu 1, naznačen time, da se klorometil-oksazolidinon spoj formule VII, pretvara u koraku (b) u derivat acetila spoja formule VI, kako je definirano u zahtjevu 1, gdje se izvodi reakcija spomenutog klorometiloksazolidinona s bezvodnim natrijevim acetatom, kako bi se dobio spoj acetila formule VI:
The use according to claim 3, wherein the non-selective beta blocker is selected from the group comprising alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propafenone, propranolol, sotalol, timolol, pharmaceutically acceptable salts therof and mixture thereof. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je ne-selektivni beta blokator odabran iz skupine koja se sastoji od alprenolola, karteolola, levobunolola, mepindolola, metipranolola, nadolola, oksprenolola, penbutolola, pindolola, sotalola, timolola, njihovih farmaceutski prihvatljivih soli i smjesa.
As noted hereinabove, ET 743 has limited aqueous solubility, see for example van Kesteren, Ch., et al., 2003, Anti-Cancer Drugs, 14 (7), pages 487-502. 
Kao što je zabilježeno u prethodnom tekstu, ET 743 ima ograničenu topljivost u vodi, pogledajte npr. van Kesteren, Ch., et at, 2003, Anti-Cancer Drugs, 14 (7), str. 487-502.
The invention also comprises a multilayer extruded slab. 
Ovaj izum također obuhvača 1 višeslojnu ekstrudiranu ploču.
providing an aminooxy compound comprising a second reactive group, wherein the aminooxy compound is chosen from compounds of Formula II: wherein Y is the second reactive group, Z is chosen from alkyl, alkenyl, alkynyl, heteroaryl, aryl, and heterocyclyl, and P is chosen from amino protecting groups; and 
osiguravanje aminooksi spoja koji sadrži aminooksi skupinu i drugu reaktivnu skupinu, pri čemu je aminooksi spoj odabran od spojeva s Formulom III: pri čemu n je odabran od cijelih brojeva u rasponu od 1 do 10, P je odabran od amino zaštitnih skupina, i Y je druga reaktivna skupina; i
A crystalline form, designated form A, of S-acetyl-glutathione (SAG), characterised by an X-ray powder diffraction spectrum, obtained using the a1 and a2 radiations of copper at 1.54060 Å and 1.54439 Å respectively, having characteristic peaks, expressed in degrees 2-theta [°], at 5.2, 10.3, 15.4, 18.6, 19.7, 35.3, and 36.3±0.2. 
Kristalinični oblik S-acetil-glutationa (SAG) označen kao oblik A, naznačeno time da rentgenski difraktogram praška, dobiven upotrebom 0, i a2 zračenja bakra pri 1.54060A odnosno 1.54439A, ima karakteristične signale, izražene u stupnjevima 2-theta ["], pri 5.2, 10.3, 15.4, 18.6, 19.7, 35.3, 36.3 # 0.2.
Preferably, the fluorescence window includes an outer surface and the outer surface of the fluorescence window is perpendicular to the outer surface of the light entry window. 
Sustav kazete za analizu prema zahtjevu 11, naznačen time, da fluorescentni prozorčić (170) uključuje vanjsku površinu, te time, da je vanjska površina fluorescentnog prozorčića okomita na vanjsku površinu prozorčića za svjetlosni ulaz (1724).
combining a compound of claim 1 with a pharmaceutical excipient to form a pharmaceutical composition; 
(a) kombiniranje spoja u skladu s patentnim zahtjevom 1 s farmaceutskim ekscipijentom kako bi se dobilo farmaceutski pripravak;